A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis.

Trial Profile

A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Pacritinib (Primary)
  • Indications Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors S*BIO
  • Most Recent Events

    • 18 Mar 2015 According to a CTI BioPharma Media Release, study design and results are presented in Blood.
    • 16 Mar 2015 Results published in the CTI BioPharma Media Release.
    • 10 Dec 2013 Pooled analysis of patients with no more than 100,000 platelets/microL at baseline presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top